If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
400.00    0.00 (0.00%)
Bid:
395.00
Ask:
405.00
Spread: 10.00 (2.532%)
Market Cap: £191.99m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

EPA approval received

23 Apr 2018 07:00

RNS Number : 6996L
Tristel PLC
23 April 2018
 

 

Tristel plc

("Tristel" or "the Company")

 

EPA approval received

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that the United States Environmental Protection Agency ("EPA") has registered its foam-based chlorine dioxide product, Duo. This registration enables Tristel to market Duo to clean and disinfect hard, non-porous surfaces. The federal registration will be followed by state-by-state approvals which the Company expects to complete by the end of 2018. The Company anticipates first revenues from the United States during its 2018-19 financial year.

 

Paul Swinney, CEO of Tristel plc, comments: "We have achieved our first United States regulatory approval, and we will continue to pursue further registrations with the EPA and the Food and Drug Administration ("FDA") to build a broadly-based business in the USA.

 

"We recently announced that we have appointed Parker Laboratories Inc to manufacture Duo in its FDA approved facility in New Jersey, and to sell Duo into the ultrasound marketplace in which they have national sales coverage. We will sell our products through different channels into other clinical areas in the USA hospital market.

 

"This first United States approval is a very significant step for our Company as it enables us to access the largest healthcare market in the world. It has been our long-held ambition to be recognised as a global brand in the infection prevention industry. An active presence in the United States is necessary to achieve this ambition, and now we can build upon the foundation stone laid in our collaboration with Parker to progress confidently towards our goal."

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

finnCap

Tel: 020 7220 0500

Geoff Nash/ Giles Rolls (Corporate Finance)

Alice Lane (Corporate Broking)

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKBDNQBKDPQB
Date   Source Headline
20th Nov 201910:08 amRNSIssue of Equity
18th Nov 20197:00 amRNSUpdate on MobileODT strategic investment
1st Nov 20194:00 pmRNSAudited accounts and notice of AGM
30th Oct 20192:25 pmRNSIssue of Equity
16th Oct 20197:00 amRNSFinal Results
14th Oct 201911:43 amRNSIssue of Equity
13th Sep 20193:58 pmRNSIssue of Equity
10th Sep 201910:27 amRNSHolding(s) in Company
28th Aug 20197:00 amRNSIssue of Equity
21st Aug 20197:00 amRNSInvestor results presentation
7th Aug 201910:31 amRNSIssue of Equity
31st Jul 20193:45 pmRNSHolding(s) in Company
22nd Jul 20197:00 amRNSTrading update, Acquisition & Notice of Results
12th Jun 20197:00 amRNSIssue of Equity
5th Jun 20197:00 amRNSShareholder Open Day
17th May 20191:58 pmRNSIssue of Equity
10th May 201910:26 amRNSHolding(s) in Company
1st Apr 20197:00 amRNSRegulatory approvals in China and South Korea
26th Mar 20197:00 amRNSHolding(s) in Company
6th Mar 20197:00 amRNSIssue of Equity
4th Mar 20192:31 pmRNSIssue of Equity and PDMR Dealing
1st Mar 20193:42 pmRNSDirector/PDMR Shareholding
25th Feb 20197:00 amRNSHalf-year Report
5th Feb 20197:00 amRNSDirector Appointment
14th Jan 20195:26 pmRNSDirector/PDMR Shareholding
14th Jan 201912:00 pmRNSInvestor results presentation
11th Dec 201810:49 amRNSResult of AGM
11th Dec 20187:00 amRNSAGM Statement and notice of results
19th Nov 201811:31 amRNSDirector/PDMR Shareholding
19th Nov 20187:00 amRNSAcquisition & Board Appointment
5th Nov 20188:35 amRNSIssue of Equity
17th Oct 20187:00 amRNSFinal Results
13th Sep 20187:00 amRNSNotice of Results
24th Aug 20187:00 amRNSIssue of Equity
23rd Aug 20187:00 amRNSIssue of Equity
19th Jul 20184:21 pmRNSHolding(s) in Company
19th Jul 20183:55 pmRNSHolding(s) in Company
16th Jul 20185:49 pmRNSResult of secondary placing
16th Jul 20181:53 pmRNSProposed secondary placing of Ordinary Shares
13th Jul 20187:00 amRNSTrading update & Notice of results
12th Jun 20184:39 pmRNSIssue of Equity
11th Jun 20182:37 pmRNSDirector/PDMR Shareholding
8th Jun 20187:00 amRNSShareholder Open Day
7th Jun 20188:15 amRNSIssue of Equity
1st Jun 20183:50 pmRNSDirector/PDMR Shareholdings
15th May 20188:14 amRNSHolding(s) in Company
11th May 20185:45 pmRNSDirector/PDMR Shareholding
10th May 20188:26 amRNSHolding(s) in Company
8th May 20189:51 amRNSIssue of Equity
2nd May 20184:55 pmRNSDirector/PDMR Dealing and Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.